Clinical Research Directory

Inclusion Criteria: * Age between 18 and 75 years, regardless of gender. * Diagnosis of AML (excluding APL) according to the 2022 World Health Organization (WHO) diagnostic criteria. * ECOG performance status of 0-2. * For female participants of childbearing potential or male participants with female partners of childbearing potential, effective contraceptive measures must be taken throughout the entire treatment period and for 6 months after the treatment period. * Expected survival of at least 3 months. * Ability to understand and willingness to participate in the study, and signing an informed consent form. Exclusion Criteria: * Acute promyelocytic leukemia (M3 subtype). * Central nervous system leukemia. * Severe uncontrolled infection or other major diseases. * Heart failure: Ejection fraction (EF) \< 50%, New York Heart Association (NYHA) class II or above. * Impaired liver or kidney function: Serum total bilirubin ≥ 2.0 mg/dl, AST ≥ 3 times the upper limit of normal, serum creatinine clearance rate (Ccr) ≥ 50 ml/min, arterial oxygen saturation (SpO2) \< 92%. * Human immunodeficiency virus (HIV) positive. * Active hepatitis B or C. * Pregnant or lactating women. * Other conditions in which the investigator deems the participant unsuitable for the study.